Skip to content

Health effects of some medicines used to control high blood pressure or fast heart rate

Behavioral changes and extra-pyramidal symptoms in elderly patients on L-type calcium channel blockers. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106475
Enrollment
120
Registered
2026-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10-I16- Hypertensive diseases Health Condition 2: I49- Other cardiac arrhythmias

Interventions

Intervention1: Calcium channel blockers: Any one out of Amlodipine 2.5 mg to 10 mg Cilnidipine 10 mg to 20 mg Nifedipine 10 mg to 60 mg (All doses- based on clinical judgement
continued as long as indicated as per prevalent guidelines for blood pressure control or till adverse event warrants cessation of therapy) Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4
continued as long as indicated as per prevalent guidelines for heart rate control or till adverse event warrants cessation of therapy) Control Intervention1: Other medicines for hypertension: Any one
continued as long as indicated as per prevalent guidelines for blood pressure control or till adverse event warrants cessation of therapy) Control Intervention2: Other medicines for tachyarrhythmias o
continued as long as indicated as per prevalent guidelines for heart rate control or till adverse event warrants cessation of therapy)

Sponsors

BANARAS HINDU UNIVERSITY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Elderly patients who are more than/equal to 60 years of age and diagnosed with hypertension or tachycardia/tachyarrhythmia and started on CCBs or other anti hypertensives or started on CCBs or other rate controlling agents and who give consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients with below mentioned conditions shall be excluded Associated dementia Established neuropsychiatric disorders at baseline Serious illnesses like myocardial infarction or stroke which may deem recruitment in study unfavorable as per treating geriatrician Serious acute illness requiring hospitalization Significant hearing or speech or vision loss which makes communication impossible

Design outcomes

Primary

MeasureTime frame
Behavioral changesTimepoint: at baseline 1 month 3 month 6 month and 12 month

Secondary

MeasureTime frame
Motor disordersTimepoint: at baseline 1 month 3 month 6 month and 12 month;Quality of lifeTimepoint: at baseline 1 month 3 month 6 month and 12 month;Cognitive statusTimepoint: at baseline 1 month 3 month 6 month and 12 month;Depression statusTimepoint: at baseline 1 month 3 month 6 month and 12 month;Functional statusTimepoint: at baseline 1 month 3 month 6 month and 12 month;Adverse eventsTimepoint: at baseline 1 month 3 month 6 month and 12 month;Motion sensor data- exploratoryTimepoint: at baseline 1 month 3 month 6 month and 12 month- optional

Countries

India

Contacts

Public ContactSankha Shubhra Chakrabarti

Institute of Medical Sciences Banaras Hindu University

sankha.chakrabarti1@bhu.ac.in8874452095

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026